Is the GLP-1 pill as good as the shot?
Short answer: not quite, but it is close enough to matter. The first oral GLP-1, orforglipron (brand name Foundayo), produced about 12.4% body weight loss at its highest dose over 72 weeks in the ATTAIN-1 trial (N Engl J Med. 2025; DOI: 10.1056/NEJMoa2511774). That lands near injectable semaglutide (Wegovy) at about 14.9% and below injectable tirzepatide (Zepbound) at about 20.9%. The pill is a real tool. It is just not the strongest one in the drawer.
What is orforglipron (Foundayo)?
Orforglipron is the first small-molecule, non-peptide oral GLP-1 receptor agonist FDA approved for chronic weight management. The FDA approved it on April 1, 2026. Unlike oral semaglutide (Rybelsus), which must be taken on an empty stomach with a small sip of water and a 30-minute fast, orforglipron can be taken any time of day with no food or water restrictions.
How much weight do you lose on the pill?
In ATTAIN-1 (3,127 adults with obesity, without diabetes), the highest dose reduced body weight by about 12.4%, roughly 27.3 lbs, over 72 weeks versus about 2% on placebo (N Engl J Med. 2025; DOI: 10.1056/NEJMoa2511774). In ATTAIN-2 (adults with type 2 diabetes), weight loss reached up to about 9.6% at the highest dose (Lancet. 2025; DOI: 10.1016/S0140-6736(25)02165-8). Weight loss with type 2 diabetes is typically somewhat lower across this drug class.
Pill vs injection: the head-to-head numbers
| Medication | Route | Approx. weight loss | Trial |
|---|---|---|---|
| Orforglipron (Foundayo) | Oral pill | ~12.4% | ATTAIN-1 |
| Semaglutide (Wegovy) | Weekly injection | ~14.9% | STEP-1 (PMID: 33567185) |
| Tirzepatide (Zepbound) | Weekly injection | ~20.9% | SURMOUNT-1 (PMID: 35658024) |
These figures come from separate trials, not a single head-to-head study, so treat them as ranges rather than a photo finish. The pattern is still clear: the pill sits at the lower end of the injectable range.
Who is the GLP-1 pill actually right for?
The pill is often the right first tool for someone who has avoided GLP-1 therapy because of needle aversion, storage or refrigeration concerns, or the complexity of weekly injections. The most effective medication is the one a patient will consistently take. For patients whose primary goal is the largest possible weight reduction and who are comfortable injecting, tirzepatide still leads on raw magnitude. This is a decision best made with a clinician who can weigh your history, your goals, and your tolerability.
How much does the pill cost?
Self-pay pricing for the lowest dose starts around $149/month. Eligible patients with commercial insurance may pay as little as $25/month with a manufacturer savings card, and eligible Medicare Part D patients may access it for about $50/month beginning July 1, 2026 (Eli Lilly and Company, 2026).
Frequently asked questions
Is orforglipron the same as Ozempic?
No. Ozempic is injectable semaglutide. Orforglipron is a different molecule taken as a daily pill.
Can you take the pill with food?
Yes. Orforglipron has no food or water timing restrictions, which sets it apart from oral semaglutide.
Is the pill safer than the shot?
Side effects across the GLP-1 class are mostly gastrointestinal and generally mild to moderate. The pill’s safety profile in trials was similar to other GLP-1 receptor agonists. Individual risk should be assessed by a clinician.
Will the pill work if the shot did not?
Not necessarily, and possibly less so given the lower average weight loss. This is worth discussing with a provider.
Ready to figure out which tool fits you?
Book a metabolic consult with Natalie Howard, DNP, MBA, FNP-C, MSN, RN at Moxie Wellness.
Free download — the 5 metabolic labs to ask for:
Before you start any GLP-1, know your baseline. Get the 5 metabolic labs I tell patients to ask for, in plain English: Get the free guide.
Medical disclaimer: This article is educational and not medical advice. It does not create a provider-patient relationship. Consult a licensed clinician before starting, stopping, or changing any medication.